

1 November 2018

Release of the 2018/19 Invitation to Tender

The 2018/19 Invitation to Tender (2018/19 ITT) has been distributed today.

If you have already registered your e-mail address with PHARMAC's new tendering e-portal you can access the 2018/19 ITT in the e-portal in Current Tenders.

If you have not registered your company with the e-Portal, and you would like to participate in the 2018/19 ITT, please register at <https://in-tendhost.co.uk/pharmac/asp/Home>.

A complete copy of the 2018/19 ITT is available on our website at the following link <https://www.pharmac.govt.nz/news/tenders>. We will not be posting out any hard copies of the 2018/19 ITT.

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to PHARMAC no later than **5pm** (New Zealand time) on **Monday 17 December 2018**.

Changes to the 2018/19 ITT product list

Please note that the product list (Schedule Two) consulted on in August 2018 has changed. Some products have been added, removed or amended either as a result of:

- clinical advice received (i.e. from the Tender Medical Evaluation Subcommittee of PTAC and/or members of the Hospital Pharmaceuticals Subcommittee); and/or
- consultation responses received from suppliers, DHBs and/or medical groups; and/or
- a review of unresolved bids from previous tenders; and/or
- Alternative Commercial Proposals accepted by PHARMAC.

The following items have been added to the 2018/19 ITT:

Chemical Name	Line Item
Buprenorphine with naloxone	Tab sublingual 2 mg with naloxone 0.5 mg
Buprenorphine with naloxone	Tab sublingual 8 mg with naloxone 2 mg
Caspofungin [whole market]	Inj 50 mg
Cetrimide	Soln 20% (pack size of 100 ml or less)
Dimethicone	Crn 5% (pack size 100 g or less)
Fluconazole	Inj 2 mg per ml

Chemical Name	Line Item
Hydrogen peroxide	Soln 3% (10 vol)
Imipenem with cilastatin	Inj 500 mg with cilastatin 500 mg
Methadone hydrochloride	Tab 5 mg
Mitomycin C	Inj 10 mg – 20 mg

The following items that were included in consultation have been removed from the 2018/19 ITT:

Chemical Name	Line Item
Abiraterone acetate	Tab 250 mg
Articaine hydrochloride	Inj 1%
Articaine hydrochloride with adrenaline	Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge
Articaine hydrochloride with adrenaline	Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge
Articaine hydrochloride with adrenaline	Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge
Articaine hydrochloride with adrenaline	Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge
Benzocaine	Gel 20%
Benzydamine hydrochloride	Soln 0.15%
Benzydamine hydrochloride	Spray 0.15%
Benzydamine hydrochloride	Spray 0.3%
Carbomer	Ophthalmic gel 0.3%
Codeine phosphate	Tab 15 mg
Codeine phosphate	Tab 30 mg
Codeine phosphate	Tab 60 mg
Diphenoxylate hydrochloride with atropine sulphate	Tab 2.5 mg with atropine sulphate 25 mcg
Disodium edetate	Inj 150 mg per ml, 20 ml
Doxycycline	Tab 100 mg
Glyceryl trinitrate	Spray 400 mcg per dose
Hexamine hippurate	Tab 1 g
Ipratropium bromide	Nebuliser soln , 250 mcg per ml, 2 ml
Isosorbide mononitrate	Tab long-acting 40

Chemical Name	Line Item
	mg
Ketoconazole	Tab 200 mg
Lidocaine [Lignocaine] hydrochloride	Inj 2%, 5 ml, sterile pack
Lidocaine [Lignocaine] hydrochloride	Inj 1%, 5 ml, sterile pack
Lincomycin	Inj 300 mg per ml, 2ml
Macrogol 400 and propylene glycol	Eye drops, preservative free
Magnesium oxide	Cap 663 mg (400 mg elemental)
Metronidazole	Inj 5 mg per ml, 100 ml bottle
Oily phenol	Inj 5%, 5 ml
Oxymetazoline hydrochloride	Aqueous nasal spray 0.25 mg per ml
Oxymetazoline hydrochloride	Aqueous nasal spray 0.5 mg per ml
Paraffin	Oral liq 1 mg per ml
Posaconazole	Oral liq 40 mg per ml
Posaconazole	Tab modified-release 100 mg
Sodium acid phosphate	Enema 16% with sodium phosphate 8%
Sodium citrate	Powder
Sodium hyaluronate [hyaluronic acid]	Eye drops 1 mg per ml
Sulphur	Precipitated
Vincristine sulphate	Inj 1 mg per ml, 1 ml
Xylometazoline hydrochloride	Aqueous nasal spray 0.05%
Xylometazoline hydrochloride	Aqueous nasal spray 0.1%
Xylometazoline hydrochloride	Nasal drops 0.05%
Xylometazoline hydrochloride	Nasal drops 0.1%

The following items have been amended in the 2018/19 ITT:

Chemical Name	Line Item
Aciclovir	Eye oint 3%
Aluminium hydroxide with magnesium hydroxide and simethicone	Tab 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg
Azathioprine	Tab 25 mg
Bendamustine	Inj 100 mg vial
Bendamustine	Inj 25 mg vial
Betamethasone	Inj 4 mg per ml, 1 ml
Betamethasone	Tab 500 mcg
Betaxolol hydrochloride	Eye drops 0.25%
Betaxolol hydrochloride	Eye drops 0.5%
Brimonidine tartrate with timolol	Eye drops 0.2% with timolol maleate 0.5%
Busulfan	Inj 6 mg per ml
Calcium folinate	Inj 3 mg
Calcium folinate	Inj 50 mg
Calcium folinate	Tab 15 mg
Capsaicin	Crn 0.025%
Capsaicin	Crn 0.075%
Carboxymethylcellulose	Oral spray
Caspofungin	Inj 50 mg
Caspofungin	Inj 70 mg
Coal tar	Soln BP
Dacarbazine	Inj
Dapsone	Tab 100 mg
Dapsone	Tab 25 mg
Dexamethasone	Eye drops 0.1%
Dexamethasone	Eye oint 0.1%
Disodium edetate	Inj 150 mg per ml, 20 ml – 100 ml
Doxycycline	Tab 20 mg – 50 mg
Erythromycin stearate	Tab 250 mg
Erythromycin stearate	Tab 500 mg
Etoposide	Inj 20 mg per ml, 5 ml
Etoposide	Cap 50 mg
Etoposide	Cap 100 mg
Fluorometholone	Eye drops 0.1%
Furosemide [Frusemide]	Inj 10 mg per ml, 2 ml
Hydrocortisone with Cinchocaine	Oint 5 mg with cinchocaine hydrochloride 5 mg per g

Chemical Name	Line Item
Hydrocortisone with Cinchocaine	Suppos 5 mg with cinchocaine hydrochloride 5 mg per g
Iloprost	Inj 50 mcg per ml, 0.5 ml
Ipratropium bromide	Nebuliser soln, 250 mcg per ml, 1 ml - 2 ml
Levetiracetam	Tab 1 g
Levetiracetam	Tab 250 mg
Levetiracetam	Tab 500 mg
Levetiracetam	Tab 750 mg
Levonorgestrel	0.75 mg - 1.5 mg
Lidocaine [Ligocaine] hydrochloride with chlorhexidine	Gel 2% with 0.05% chlorhexidine, 10 ml urethral syringe
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg
Magnesium Salt	Tab
Meloxicam [current access]	Tab 7.5 mg
Mesna	Tab 400 mg
Mesna	Tab 600 mg
Methyl Hydroxybenzoate	Powder
Metronidazole	Inj 5 mg per ml, 100 ml
Moxifloxacin	Inj 400 mg
Nitazoxanide	Tab 500 mg
Olopatadine	Eye drops 0.1%
Oxybutynin	Oral liq 1 mg per ml
Pholcodine	Oral liq 1 mg per ml
Retinol palmitate	Eye oint 138 mcg per g
Ropivacaine hydrochloride with fentanyl	Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag
Ropivacaine hydrochloride with fentanyl	Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag
Sodium alginate with	Oral liq 500 mg with

Chemical Name	Line Item
sodium bicarbonate and calcium carbonate	sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml
Sodium alginate with sodium bicarbonate and calcium carbonate	Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg
Sodium cromoglicate	Eye drops 2%
Sodium fusidate [fusidic acid]	Eye drops 1%
Sucrose	Oral liq 25%
Temozolomide	Cap 100 mg
Temozolomide	Cap 140 mg
Temozolomide	Cap 20 mg
Temozolomide	Cap 250 mg
Temozolomide	Cap 5 mg
Teriparatide	Inj 250 mcg per ml

Chemical Name	Line Item
Tobramycin	Eye drops 0.3%
Trimethoprim and sulphamethoxazole [co-trimoxazole]	Tab trimethoprim 80 mg - 160 mg and sulphamethoxazole 400 mg - 800 mg
Tropicamide	Eye drops 0.5%
Tropicamide	Eye drops 1%
Vincristine sulphate	Inj 1 mg per ml, 1 - 2 ml
Zidovudine	Cap 100 mg
Zidovudine	Oral liq 10 mg per ml
Zidovudine	Inj 10 mg per ml, 20 ml vial
Zoledronic Acid	Inj 5 mg
Zopiclone	Tab 7.5 mg

Appropriate pack-size and packaging type

Where possible, PHARMAC has identified Tender Items where there is a specific preference for a pack size or packaging type in Schedule Two of the 2018/19 ITT document. For example (highlighted in red):

SCHEDULE TWO: PRODUCTS TO BE TENDERED						
Chemical Name	Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Allopurinol	Tab 100 mg	18,654,466	\$296,606	\$0.0159	C H 1%	A scored tablet is preferred
	Tab 300 mg	12,764,511	\$427,611	\$0.0335	C H 1%	A scored tablet is preferred
Amantadine hydrochloride	Cap 100 mg	674,910	\$430,143	\$0.6373	C H 1%	
Amikacin	Inj 15 mg per ml, 5 ml				H 1%	Preference for syringes

While PHARMAC has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids.

Oncology injectables

DHBs are increasingly delivering chemotherapy treatment in satellite centers which require compounded products to have a shelf-life greater than 24 hours to account for delays in

treatment transport and delivery. Due to this PHARMAC has indicated a preference for products where stability data post-compounding is greater than 48 hours.

Ophthalmology Products (BAK-free)

For a number of Ophthalmology products, as indicated in Schedule Two of the 2018/19 ITT document, PHARMAC reserves its right to list a benzalkonium chloride (BAK) or preservative-free product for a restricted market. However, where a tender product is BAK-free it would have the entire market.

Intra-Uterine Copper Devices (IUCDs)

PHARMAC have included a new schedule, schedule 7, in the 2018/19 Invitation to Tender relating to special terms for the supply of IUCDs. PHARMAC may request tenderers to provide a proposal and evidence of the Resources and Related Products after the submission of a tender bid for IUCDs.

Data estimates for PCT injectable products included in the 2018/19 ITT

PHARMAC makes no representation as to the accuracy of this information or as to the level of sales or likely sales and, while PHARMAC has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information.

In order to be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2018/19 ITT remains open.

Usage data for PCT injectable products

Chemical	Total usage (mg)¹
Bendamustine	137,897
Bortezomib	24,938
Busulfan	60
Calcium folinate	3,804,695
Dacarbazine	65,485,756
Doxorubicin	462,934
Etoposide	1,196,534
Fludarabine phosphate	708,935
Fluorouracil sodium	44,671,283
Gemcitabine hydrochloride	9,758,248
Mesna	5,915,174
Methotrexate	5,688,348
Mitomycin	7,229

Pemetrexed	96,220
Vincristine sulphate	10,486
¹ Usage in mg, for period between 1 January 2017 to 31 December 2017 These volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item.	

Transition period

PHARMAC have included provisions in the 2018/19 Tender modifications of the transition period for brand changes made to community medicines.

In summary, reference pricing has been removed from the transition period of brand changes in the community (Section B of the Pharmaceutical Schedule). The first transition period of a brand change will now be aligned in the community and DHB hospitals.

For Additional Stock Pharmaceuticals (ASPs) or other products where PHARMAC requires suppliers to hold four months of stock, PHARMAC will provide at least two months written notice of another supplier's brand of the Pharmaceutical being listed and a seven-month first transition period.

More information

If you have any queries regarding the tender or require any assistance with the e-portal please contact the Tender Analysts at tender@pharmac.govt.nz.